Iohexol is a non-ionic contrast agent, which has been widely described in recent literature as an accurate marker for the measurement of glomerular filtration rate (GFR). Our aim was to establish a capillary electrophoresis assay, based on a previously described method, that had adequate reproducibility to be used as part of a clinical trial. In this paper, we examine the practical aspects, pitfalls and steps we took to achieve a precise and reproducible assay. To minimize laboratory variation, we examined properties such as the use of an internal standard in a capillary electrophoresis separation, alternative deproteinization methods for serum, the most suitable matrix for the dilution of standards and the implementation of suitable quality control material to ensure that run-to-run variability was minimized. The optimized capillary electrophoretic assay of iohexol was found to be robust, with over 860 runs from the one capillary over a 9-month period. Excluding capital costs of the instrument, the consumable cost of the assay is less than A$0·25 per test, with a run time of 5·25min and a coefficient of variation (CV) of 4·3% at 80mg/L. The GFR, calculated from the plasma clearance, had a reproducibility of 5·47%.
SUMMARY. Iohexol is a non-ionic contrast agent, which has been widely described in recent literature as an accurate marker for the measurement of glomerular filtration rate (GFR). Our aim was to establish a capillary electrophoresis assay, based on a previously described method, that had adequate reproducibility to be used as part of a clinical trial. In this paper, we examine the practical aspects, pitfalls and steps we took to achieve a precise and reproducible assay. To minimize laboratory variation, we examined properties such as the use of an internal standard in a capillary electrophoresis separation, alternative deproteinization methods for serum, the most suitable matrix for the dilution of standards and the implementation of suitable quality control material to ensure that run-to-run variability was minimized. The optimized capillary electrophoretic assay of iohexol was found to be robust, with over 860 runs from the one capillary over a 9-month period. Excluding capital costs of the instrument, the consumable cost of the assay is less than A$0·25 per test, with a run time of 5·25min and a coefficient of variation (CV) of 4·3% at 80mg/L. The GFR, calculated from the plasma clearance, had a reproducibility of 5·47%.
Glomerular filtration rate (GFR) is routinely used to measure renal function in the management of progressive renal disease and for determining the dose of nephrotoxic drugs excreted by the kidney. GFR is an important endpoint in assessing therapeutic intervention in patients with renal disease, in particular diabetic nephropathy.
Reproducibility of GFR measurement is dependent on both biological and methodological variation. A previous study of intraindividual variability in triplicate GFR measurements using iohexol measured by high-performance liquid chromatography (HPLC) showed a reproducibility of 6·28% in patients with a wide range of renal function.I Biological variation has been estimated to be as high as 10%,2 but can be minimized by performing the test under standardized conditions. The reproducibility of a test for GFR Correspondence: Margaret A Jenkins. E-mail: majenkins@austin.unimelb.edu.au determines its ability to detect true changes in renal function. In general, the difference between two measurements in the same subject is ex ected to be less than (2 x 1.96 x standard deviation) for 95% of pairs of observations. This translates to an approximate 16% difference between measurements to be necessary for a true change in GFR to be detected when the CV of a test is 6%. In the setting of a clinical trial, a reproducible method of analysis is required which will minimize the variability of GFR measurement, and therefore improve the ability to detect changes in renal function.
In Australia, GFR is usually measured by plasma clearance of radioisotopes. Plasma clearance of iohexol has been widely reported in the recent literature as an accurate measure of GFR. Our aim was to set up, at our institution, a non-radioactive method for GFR assessment using iohexol (N,N-bis (2,3-dihydroxypropyl)-5-N-(2,3-dihydroxypropyl) acetamido-2,4,6-triiodoisophthalamide). Iohexol has been measured by both HPLC 2-5 and capillary electrophoresis.Y We chose the latter because of existing expertise with this technique.
Capillary electrophoresis (CE) is an extremely sensitive technique which uses thin buffer-filled capillaries to obtain separations in minutes by the application of an extremely high voltage. A significant advantage of CE is its excellent reproducibility. The consumable cost of CE is low, and, because there are no pumps to manipulate, it is easier to operate than HPLC. Capillary zone electrophoresis (CZE), which is the simplest form of CE, has been used for the analysis of amino acids, peptides and ions. In the clinical laboratory, CZE has been used predominantly to automate serum protein electrophoresis.I:? although separations for drug analysis such as pentobarbital and iohexol, JO vitamins'U! and haemoglobin variants'<" have also been published.
The previously published method for iohexol did not explore the potential pitfalls when assaying iohexol by CEo First, the use of an internal standard to standardize the results was not explained. Second, although the preparation of an iohexol standard was detailed, the dilution of this relatively high concentration of iohexol in either an aqueous or a serum matrix was not considered. Third, there were no stability studies regarding the frozen standard over a 6-month period. Also, to use the published method in a clinical trial requires incorporation of quality control to ensure that results are reproducible within specified limits; however, commercial quality controls for iohexol are not yet available.
METHODS

Apparatus
A BioFocus 2000 capillary electrophoresis system (Bio-Rad, Hercules, USA) with a standard 24 em x 50 Jlm (internal diameter) fused-silica capillary (Scientific Glass Engineering, Ringwood, Australia), contained in a cassette, was used for separation. Detection was performed at the cathodic end by oncolumn measurement of absorbance at 254 nm. The analysis was otherwise performed according to the previously published method of Shihabi," except that the washing procedure of 2 min with 50mmol/L phosphoric acid, I min with distilled water, 2min with 100mmoi/L sodium hydroxide, I min with distilled water and 2 min with assay buffer (220 mmol/L boric acid, pH 8 '8) was performed after each sample. This was in contrast to Shihabi's method in which washing Ann Clin Biochem 2000: 37 was performed 'daily or whenever the retention time of the standards changed'. The sample was injected at 55 kPa sec, and the separation performed at 6kV.
Sample preparation
Samples were collected into tubes without anticoagulant. Serum was separated on arrival in the laboratory and stored at 4°C until processed. To assay iohexol we used 100JlL of serum. This was deproteinized with 200 JlL of acetonitrile which contained 20 mg/L 3-isobutyl-I-methylxanthine as internal standard.' The specimens were individually vortexed for 20 s and then spun at 13000 rpm for 3 min. Capped 0'5-mL polymer tubes containing 200 JlL of each supernatant were then placed on the carousel of the instrument ready for analysis.
Standard
The iohexol stock standard 8 giL (D 2158; Sigma, St Louis MO, USA) was diluted in phosphate buffer pH 7·4 containing 60 g of bovine albumin and 0·145 mol of NaCI per litre." The stock standard was aliquoted and frozen at -70°C. Standards were diluted in normal iohexol-free serum obtained from a healthy laboratory subject. A standard curve with iohexol concentrations of 20, 40, 80 and 160mg/L was created and calibration was checked with each assay by the inclusion of three quality control (QC) specimens. New standard was prepared every 2 months (see Discussion). Recalibration was not performed after the initial calibration of the capillary if all three QC samples were within ±2 standard deviations of their mean values.
Quality control (Qq material QC specimens were prepared from Omnipaque 300 (647mg iohexol per mL) (Nycomed Australia Pty. Ltd, Chatswood, Australia) and included with each run. One millilitre of the Omnipaque 300 weighed 1·278g. By accurate weighing of 0·316 g of Omnipaque a control containing 160mg/L iohexol was prepared. This control material was stored at 4°C, and diluted in iohexol-free serum for each run to give three controls of 80, 40 and 20mg/L. For each QC, 100JlL was deproteinized with 200 JlL of acetonitrile containing the internal standard, as in the sample preparation step. New QC samples were prepared every 2 months with overlapping assays.
The iohexol concentration for each sample and QC was calculated using the ratio of the area under the curve of iohexol divided by the area under the curve of the internal standard." .s
We repeated measurement of the patients' samples 4 h after the original assay, the samples remaining untouched on the instrument. This procedure was trialled twice, a total of five patients or 25 samples being tested, as well as QC specimens. The patients' samples and QC were read off the usual standard curve in use at that time. The QC gave acceptable results. However, the patients' samples gave substantially different clearance values.
Samples repeated after 2 months of storage at 4"C showed almost identical iohexol values and no obvious breakdown products. The standard iohexol was stored at -70"C. At 6 months an aliquot of the standard was re-run by CE, and no iohexol peak was found. We had previously checked the frozen standard at 3 months after aliquoting, and had found 25% deterioration of the 80, 40 and 20 rng/L standards. This 0·00 0·75 1·50 2·253·00 3·754·50 5·25 Time (min)
Calculation of GFR
For each patient, 5 mL of Omnipaque 300 was administered by intravenous injection into the antecubital vein. Blood samples (5 mL) were obtained via an intravenous cannula in the contralateral arm at 120, 150, 180, 210 and 240 min post-injection." Exact sample times were recorded. GFR was calculated from the plasma clearance of iohexol using the slope intercept method (one-compartment model) and then approximated to a two-compartment model using the Brochner-Mortensen equation. I? Reproducibility of GFR values was calculated using the formula s = J(sumd 2 ) / N, where s is standard deviation, d is difference between duplicates and N is total number of determinations."
RESULTS
An electropherogram for a 80 mgjL iohexol standard is shown in Fig. I . For samples deproteinized in 200 ilL of acetonitrile, the ratio of standard to internal standard for standards ranging from 20 to 240mgjL is shown in Table  I . It can be seen that the calculated standard values were close to the theoretical values. Serum concentrations following a 5-mL injection of Omnipaque 300 resulted in serum iohexol concentrations of between 22 and 130 mg/L in patients with normal to moderately impaired renal function. The plasma iohexol concentration versus the time after injection for three patients with GFR ranging from 43 to 114 mLjmin are shown in Fig. 2 .
The effect of different quantities of acetonitrile used in the deproteinization step was assessed. The results are given in Table 2 . ..,.. deterioration of the stock standard held at -70°C and subsequently diluted is shown in Fig. 3 . The assay buffer and acetonitrile containing the internal standard were both stored protected from light at 4°C.
Only two batches of assay buffer and acetonitrile were used during this 9-month pretrial period. Subsequently, the stability of both the assay buffer and the acetonitrile was shown to be greater than 6 months. In each case, before a new batch was introduced, a preliminary run with QC samples was performed to ascertain that the results were similar to those of the previous batch.
The effects of dilution of the stock standard iohexol in both distilled water and in iohexolfree serum are shown in Table 3 .
Following 16 assays the QC specimens were analysed; the results are shown in Table 4 . We found that the limit of detection of iohexol was IOmg/L, the assay being linear to approximately 800mg/L.
The reproducibility of GFR values from duplicate analysis of samples from 11 patients (methodological variation) was 5·47%.
No prescription drugs were found that interfered with the iohexol assay. It had previously been reported that amoxycillin causes interference, but this was not demonstrated when we studied a patient on this medication. However, a peak was found. No interference studies for haemolysis, icterus or lipaemia were carried out.
DISCUSSION
Use of internal standard
The classic approach to internal standards for HPLC is to calculate the ratio of the peak area of the standard and of the internal standard. This adjusts for small amounts of evaporation, which is necessary with a volatile precipitating agent such as acetonitrile. Important characteristics of internal standards include purity, stability, high absorption at the wavelength of detection and non-reactivity with sample components. Internal standards allow results to be normalized and correction for quantitative losses during clean-up, which may include small pipetting errors, and instrument imprecision often caused by the injection process.'? This classic use of internal standards can also be applied to drug analysis by capillary electrophoresis.
Use of standard curves Initially, a full standard curve with iohexol concentrations of 20,40, 80 and 160mg/L was created for every run of patients' samples. However, over time, the stability of the standard curves became apparent and therefore one standard curve was used and three QC specimens were included with each assay. Providing the QC was acceptable, the capillary was not recalibrated. This procedure was similar to the quantification of serum proteins by CE 7 when the capillary is calibrated on installation and checked by QC measurements every day.
Stability
Problems of stability over time, affecting both stock standards and QC samples, have been demonstrated. Although the internal standard is supposed to correct for evaporation, we found that this was not the case after samples were left standing for 4 h on the instrument. This is probably due to the evaporative nature of acetonitrile. We have noted that samples left overnight on the instrument will evaporate totally.
We also found that prolonged storage can affect specimens. As described in the results section, the standard aliquots are stable at -70°C for 2 months, reduced by 25% at 3 months and give no detectable iohexol peak at 6 months (see Fig. 3 ). Patients' samples showed stability with excellent reproducibility for more than 2 months of storage at 4°C; however, after 6 months some of the samples showed extra peaks (see Fig. 4 ), suggesting breakdown products. Hence, we conclude that the maximum storage conditions for iohexol standards and patients' samples should be 2 months at -70°C and 4°C, respectively. The degradation of iohexol stock standards stored at -70°C has Ann Clin Biochem 2000: 37 not been reported previously; this is in contrast to the findings of Krutzen et al., who stated that serum samples stored in the freezer for 6 months showed no signs of degradation.'
Serum deproteinization
Previous authors have published two methods with different deproteinization steps.5.6 The reasons for the changes were not stated. We examined deproteinization using the two methods and obtained very similar results with respect to the final GFR value.
We chose to assess further the effects of different deproteinization regimens. For deproteinization with 150, 200 and 250 ilL of acetonitrile, the QC was acceptable. However, in the case of deproteinization with 100ilL of acetonitrile the QC was unacceptable. Incomplete protein precipitation with subsequent measurement of unprecipitated proteins was likely to cause higher QC values when 100ilL of acetonitrile was used. This was because protein measurement by CE takes place at 200 nm. It seems that deproteinization regimens with acetonitrile in the range of 150-250 ilL are satisfactory. Our decision was to proceed using 100ilL of sample deproteinized with 200 ilL of acetonitrile containing 20 rng/L internal standard.
The protein binding of iohexol has been reported to be 0-1·0% and should not be a problem in this assay." Although there did not appear to be any significant difference between the two deproteinization methods, it has been noted that the acetonitrile precipitation does not remove any inorganic ions that might be present in the sample. With high ionic buffers, such as we are using, the signal-to-noise ratio is actually improved by acetonitrile precipitation. 19 Furthermore, as a result of the stacking mechanism, large sample volumes can be loaded onto the capillary, giving increased sensitivity.'?
Matrix
We studied dilution of the stock standard iohexol in both distilled water and iohexol-free serum. There was considerable variation in the area under the curve of the standards diluted in water: for example, the area for the 80 mg/L standard varied from 17000 to 43000 in different runs (Table 3 ). However, the internal standard varied in a similar manner so that the calculations of concentration were accurate. Also, aqueous standard curves generally produced slightly higher ratios of iohexol/internal standard than standard curves diluted in normal serum. However, both aqueous and serum standard curves had a correlation coefficient of > 0·98 or better. Since the matrix of the patients' samples was serum, it was decided to keep the matrix of the standard curve the same. Standard Curves for serum iohexoJ determined by HPLC had also been constructed using human serum and known amounts of iohexol."
CONCLUSION
During a long-term trial, it is important to minimize methodological variations. Areas for attention include new batches of buffer, different batches of acetonitrile containing small amounts of internal standard, and wherever possible the same pipettes and the same capillary. Prior to use in the clinical trial these variables were minimized and we were pleased to obtain over 860 runs with the one capillary over a 9-month period. This validated the washing procedure between runs, as well as demonstrating the robust nature of the assay. From an instrument perspective, we found placement of the capillary in a cassette extremely useful. A variety of different assays were being performed on the instrument on different days. These included serum protein electrophoresis and isoelectric focusing. The use of the cassette made switching from one assay to another extremely simple. If the capillary had not been contained in a cassette and changed on a daily basis, it is extremely doubtful if it would have remained viable for 9 months. Although the BioFocus contains the capillary in a cassette, instruments such as the Applied Biosystems 270A-HT capillary electrophoresis system do not use a cassette. Our experience with the 270A-HT has shown that the window of the capillary is fragile and prone to be easily broken when manipulating it within the instrument.
Although HPLC had marginally better CVs in the published literature.' CE measurement of radio-opaque compounds such as iohexol has several advantages over HPLC assays. With CE there are no packed columns to equilibrate, and the buffer is simple with no pumps or mobile phase gradient to manipulate. Also the consumable cost for CE is extremely low, being less than 25cents per test in the case of iohexol. This included the cost of the Eppendorf tube for deproteinization, sample tube, standard, internal standard, capillary and buffer. However, it did not include the cost of the initial automated equipment, nor the cassette for holding the capillary. The CE assay is rapid, being completed in 5·25min. Our conclusion is that CE is an acceptable method for the measurement ofGFR with iohexol, and is suitable for a clinical trial.
